David Greenwood, Oliver Hague, Eliza Mari Kwesi-Maliepaard, Shanice A Redman, Flora Scott, Joshua J Anzinger, Gordon Awandare, David Lv Bauer, Yaw Bediako, Edward J Carr, Christine Vf Carrington, Adam Kucharski, Peter Quashie, Emma C Wall, Mary Y Wu
{"title":"SARS-CoV-2 antibody immunity across three continents: the West Africa, West Indies, West London Consortium.","authors":"David Greenwood, Oliver Hague, Eliza Mari Kwesi-Maliepaard, Shanice A Redman, Flora Scott, Joshua J Anzinger, Gordon Awandare, David Lv Bauer, Yaw Bediako, Edward J Carr, Christine Vf Carrington, Adam Kucharski, Peter Quashie, Emma C Wall, Mary Y Wu","doi":"10.1101/2025.06.13.25329588","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The experience of the COVID-19 pandemic has differed across continents. We hypothesized that regional differences in SARS-CoV-2 immunity might explain this observation. We therefore established the WWW Consortium in Ghana, W Africa; Jamaica, W Indies; and W London. Here, we describe the extent to which antibody immunity differs between these geographic locations.</p><p><strong>Methods: </strong>The WWW Consortium harmonises across the HERITAGE (Accra, Ghana), WINDFall (Kingston, Jamaica) and Legacy (London, UK) studies, establishing sharing frameworks for samples, metadata, and data; related permissions and oversight; and associated physical and cloud infrastructure. With centralised testing, we performed serological assessments across all three locations at two snapshots in 2024 (April 1<sup>st</sup> - August 18<sup>th</sup>; August 19<sup>th</sup> - December 31<sup>st</sup>) using high-throughput live virus neutralization and anti-nucleocapsid IgG, including n=763 individuals.</p><p><strong>Findings: </strong>We found that across all sites most participants had detectable neutralising antibody titres against JN.1 and XEC - the predominant variants in 2024. There were site-related differences in immunity: vaccine-included SARS-CoV-2 strains were better neutralised by participants from the Legacy study - Ancestral, BA.5, XBB.1.5 initially, and JN.1 after a homologous booster in autumn 2024. For HERITAGE, neutralisation of both alpha- (HCoV-229E) and beta-coronaviruses (HCoV-OC43) was higher than WINDFall suggesting a cross-coronavirus serological response in West Africa. Finally, antigenic cartography identified two distinct antibody landscapes, with JN.1 and XEC antigenically distant in Legacy, but not in HERITAGE and WINDFall.</p><p><strong>Interpretation: </strong>There is international heterogeneity in SARS-CoV-2 antibody immunity. Global recommendations for vaccine strain selection should incorporate data from diverse populations to ensure accurate, equitable recommendations.</p><p><strong>Funding: </strong>The Wellcome Trust.</p>","PeriodicalId":94281,"journal":{"name":"medRxiv : the preprint server for health sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204446/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv : the preprint server for health sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2025.06.13.25329588","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The experience of the COVID-19 pandemic has differed across continents. We hypothesized that regional differences in SARS-CoV-2 immunity might explain this observation. We therefore established the WWW Consortium in Ghana, W Africa; Jamaica, W Indies; and W London. Here, we describe the extent to which antibody immunity differs between these geographic locations.
Methods: The WWW Consortium harmonises across the HERITAGE (Accra, Ghana), WINDFall (Kingston, Jamaica) and Legacy (London, UK) studies, establishing sharing frameworks for samples, metadata, and data; related permissions and oversight; and associated physical and cloud infrastructure. With centralised testing, we performed serological assessments across all three locations at two snapshots in 2024 (April 1st - August 18th; August 19th - December 31st) using high-throughput live virus neutralization and anti-nucleocapsid IgG, including n=763 individuals.
Findings: We found that across all sites most participants had detectable neutralising antibody titres against JN.1 and XEC - the predominant variants in 2024. There were site-related differences in immunity: vaccine-included SARS-CoV-2 strains were better neutralised by participants from the Legacy study - Ancestral, BA.5, XBB.1.5 initially, and JN.1 after a homologous booster in autumn 2024. For HERITAGE, neutralisation of both alpha- (HCoV-229E) and beta-coronaviruses (HCoV-OC43) was higher than WINDFall suggesting a cross-coronavirus serological response in West Africa. Finally, antigenic cartography identified two distinct antibody landscapes, with JN.1 and XEC antigenically distant in Legacy, but not in HERITAGE and WINDFall.
Interpretation: There is international heterogeneity in SARS-CoV-2 antibody immunity. Global recommendations for vaccine strain selection should incorporate data from diverse populations to ensure accurate, equitable recommendations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
